Sight Diagnostics Named to CNBC Disruptor 50 List After Year of Tremendous Momentum in Scaling its AI-Powered Sight OLO Blood Analyzer

New York, NY -- May 25, 2021 -- Sight DiagnosticsⓇ, the company delivering lab-grade Complete Blood Count (CBC) results in minutes, announced today it has been named to the CNBC Disruptor 50, an annual list of forward-thinking and fast-growing private companies whose innovations are changing the world. This award comes in the same month that the company was recognized in the health category of Fast Company 2021 World Changing Ideas awards as well as in the 2021 Medical Design Excellence Awards competition. 

Founded in 2011, Sight aims to transform blood testing through its AI-based platform that is capable of “digitizing” blood and analyzing it. Sight’s flagship product is Sight OLOⓇ - a hematology analyzer that automates the identification and quantification of different blood cell types and anomalies. OLO delivers CBC results with lab-grade accuracy in minutes from either fingerstick or venous samples. 

Sight has seen tremendous growth and business momentum over the last year including: 

• Raised $71M in Series D funding to scale commercialization 

• Increased installations 300% year-over-year for OLOs on five continents

• Deployed at Oxford University Hospitals to perform CBC for the validation of an AI-based COVID-19 screening tool that accurately rules out COVID-19 in under 30 minutes

• Signed partnership deals to distribute OLO in Europe, the Middle East, Latin America and Canada

• Grown headcount by more than 50% across offices in Israel, Europe, and the U.S. 

“We’re humbled by this recognition from CNBC after a year of such transformation and challenge for the healthcare industry,” said Yossi Pollak, CEO and co-founder of Sight Diagnostics. “I’m incredibly proud of the work our team has accomplished in bringing fast, accurate, and convenient blood testing to the world.”

To fuel Sight’s AI-driven method, the company has generated a database of approximately a petabyte of digitized blood images. This database is used to not only optimize Sight’s current diagnostic algorithms but also to explore new algorithms for the potential of early detection of serious health conditions. With an expanded commercial footprint, Sight Diagnostic’s database, one of the biggest sets of blood imagery in the world, will continue to propel the company to the forefront of blood diagnostics.

To determine nominees for the CNBC Disruptor 50, organizations were put through a comprehensive, rigorous process of researching and scoring across a wide range of quantitative and qualitative criteria, including scalability, revenue, and user growth, and workforce diversity. Sight was selected out of 1,565 applicants by an advisory board made up of leading thinkers in the field of innovation and entrepreneurship. These judges provided weighting for the quantitative criteria, while a team of more than 50 CNBC editorial staff read submissions and provided qualitative assessments of every single nominee.

Companies interested in partnering with Sight or deploying the Sight OLO analyzer can find more information at www.sightdx.com.

*In the United States, Sight OLO is 510(k) cleared for use in moderate complexity laboratories. Outside of the United States, Sight OLO is CE Marked according to the IVD European directive and cleared by the Australian TGA for point of care settings. For complete Indications for Use and safety information of Sight OLO please visit www.SightDX.com

About Sight Diagnostics

Founded in 2011, Sight Diagnostics aims to transform health systems and patient outcomes through fast, accurate and convenient blood diagnostic testing. Sight’s technology, developed over a decade of research, represents breakthrough innovations in diagnostic methodology by combining artificial intelligence (AI) with a new method for “digitizing” blood. Sight’s latest blood analyzer, Sight OLO, performs a Complete Blood Count, the most commonly ordered blood test, in minutes. OLO creates a digital version of a blood sample by capturing more than 1,000 highly detailed images from just two drops of blood obtained from a finger prick or venous sample. These images are then interpreted by proprietary and fully automated AI algorithms. Sight’s first product, ParasightTM, has been used to detect malaria in almost 1 million tests across 24 countries. The company has rapidly growing offices in the US, the UK and Israel. Learn more at www.SightDX.com.

Contact Information

Riley Munks

Media Contact

VSC for Sight Diagnostics

sight@vsc.co